

1 *ENOX1, CCDC122 AND LACC1* ROLE IN PROGRESSION OF PROSTATE CANCER ¹

2

3 Author list

4 Timothy Ongaba^{1*}

5 ¹School of Science and Technology

6 Nottingham Trent University

7 Clifton Campus

8 Clifton Lane

9 Nottingham

10 NG11 8NS

11 United Kingdom

12 Email: dextertim5@gmail.com

13

14 **Abstract**

15 Prostate cancer (PCa) continues to trend among top 3 cancers that kill men over 20 years in
16 the United Kingdom and worldwide despite extensive research and resources directed
17 towards its treatment and prevention. In the application of a hallmark of survival
18 mechanisms by the cancer, our study used mRNA seq data to identify genes that are
19 increasingly mutated with progressing PCa from a cohort of 491 PCa patients. We found
20 that *ENOX1*, *CCDC122* and *LACC1* deep deletion was positively associated with increasing
21 age of diagnosis. Pathway analysis of enriched genes, following their deep deletion
22 identified estrogen biosynthesis, KSRP signalling, omega 3 and 6 fatty acid biosynthesis
23 and, Rap1 signalling as the top 5 enriched pathways. Previous individual and combined role
24 of these genes in PCa progression was not fully established but thanks to this study, these
25 pathways could be druggable targets in PCa patients with these gene deep deletions.

26 **Introduction**

27 **Background to the investigation**

28 Prostate cancer (PCa) is the most frequently diagnosed cancer in men in 132 countries with a
29 7.3% incidence worldwide. It is the second cause of cancer deaths in men in 48 of 185 sampled
30 countries worldwide^{1,2}. One in 8 men will be diagnosed with prostate cancer in the UK while one
31 dies from the disease every 45 minutes. The number of PCa cases are projected to rise by 15%
32 in the UK between 2023 to 2025 indicating an ever-increasing trend³.

33

34 PCa starts *in-situ* within the prostate where it can, but not always, metastasize to the lymph
35 nodes, bone, lung, liver and even as far as the brain when left untreated⁴. PCa can be termed
36 localised when it remains within the prostate or metastatic when it spreads beyond the prostate.
37 Localised PCa becomes high risk based on clinical staging, biochemical recurrence and a high
38 Gleason score⁵. While still localised but more often when metastasised, PCa can progress from
39 hormone sensitive to refractory phenotype with increasing resistance to treatment and
40 decreasing survival rate from 30% over 5 to 30% over 3 years patient survival⁶.

41 When metastasised, the disease can be categorised as metastatic castration-sensitive prostate
42 cancer (mCSPC) when clinical deprivation of androgens halts cancer advancement. The disease
43 is termed castration-resistant prostate cancer (mCRPC) when cancer continues to progress even
44 in the absence of androgens. The risk of fatality significantly increases when PCa becomes
45 castration resistant⁵.

46

47 The incidence of PCa increases with age starting at 45, steeply rising and peaking around 75 to
48 79 years. Patient survival is dependent on regular screening recommended to start at 45 years,
49 early diagnosis and treatment intervention which might include chemotherapy, radiotherapy,
50 surgical resection of tumours, immunotherapy or gland ablation to reduce the role of androgens
51 in disease progression^{3,7,8}.

52

53 Tumour Mutational Burden (TMB) of PCa, the somatic cell rate of mutation per mega base pair
54 has been associated with low response to chemotherapy, high biochemical recurrence and,
55 generally poor prognosis. These together with other cofounders such as poor immune cell
56 infiltration into the tumour microenvironment, and androgen receptor status quickly lead to
57 reduced survival of affected individuals⁹⁻¹¹.

58 Among tumour mutations are gene deletions that can also appear as copy number alterations.
59 Many of these, as deep deletions at chromosome 13q have been previously linked to poor
60 prognosis in prostate cancer, high Gleason scores and biochemical recurrence¹²

61 Conversely, the high TMB also brings about high immunogenicity and, therefore, better response
62 to immunotherapy^{10,13}. This could, however apply to mutations in which the change in gene
63 sequence produces a more antigenic protein product detectable by the affected individual. A
64 deletion would lead to structural or functional alteration of the translated protein product.

65

66 Some of the most implicated genes in PCa are those involved in cell cycle progression, receptor
67 signalling, proto-oncogenes, and or tumour suppressors. Among these, *UBE2C*, *PLK1*, *CDC20*,
68 *BUB1*, *CDK1* and *HJURP* are top 6 linked to disease progression, metastasis and, poor
69 prognosis^{9,10}.

70
71 Ecto-NOX Disulfide-Thiol Exchanger 1 (*ENOX1*), also known as cCNOX, CNOX, FLJ10094, and
72 PIG38, is a copper-binding protein expressed in endothelial and other cells where it has NADH
73 oxidase activity, promotes angiogenesis and is a potential druggable target^{14–16}. It is one of the
74 genes on the 13q chromosome arm whose deletion is associated with poor prognosis, early
75 biochemical recurrence and metastasis^{12,17}.

76 *ENOX1* has been negatively associated with prostate cancer, which is characterized by structural
77 rearrangements, most frequently including translocations between androgen-dependent genes
78 and other genes¹⁸. The Protein Atlas shows that *ENOX1* is expressed in cancer tissue, including
79 prostate cancer^{19,20}. *ENOX1* shares a 66% sequence identity with *ENOX2* of the same protein
80 family with demonstrated contribution to gastric cancer cell growth and survival²¹. The exact role
81 of *ENOX1* in prostate cancer is, however, not fully understood, and further research is needed to
82 determine its functions and prognostic values¹⁶.

83
84 Coiled-Coil Domain Containing 122 (*CCDC122*) is a gene that is overexpressed in prostate
85 cancer as compared to healthy prostate tissue^{22,23}. There is generally limited literature linking the
86 gene or its products to prostate cancer and this warrants further studies following its differential
87 expression and or mutation during the progression of disease. Single nucleotide polymorphisms
88 in the gene have previously been linked to development of leprosy in case controlled cohorts of
89 Chinese and Brazilian populations^{24,25}.

90
91 The Laccase Domain-Containing 1 (*LACC1*) gene is a gene that encodes an oxidoreductase that
92 promotes fatty-acid oxidation, with concomitant inflammasome activation, mitochondrial and
93 NADPH-oxidase-dependent reactive oxygen species production, and anti-bacterial responses in
94 macrophages^{22,26–29}. In relation to prostate cancer, a transcriptome analysis of differentially
95 expressed genes in methotrexate-resistant prostate cancer found that *LACC1* was one of the
96 genes that was differentially expressed³⁰. A study aimed at identifying biomarkers for the
97 management of human prostate cancer also found that *LACC1* was one of the genes that was
98 differentially expressed in prostate cancer tissue compared to normal tissue³¹. Data from the TNM
99 plot shows a reduced expression of the gene in prostate cancer compared to normal prostate
100 tissue²³. *LACC1* has also been linked to Leprosy in similar studies as *CCDC122*^{24,25}.

101

102 **Materials and Methods**

103 **Data retrieval from cbiportal**

104 Using mRNA Seq data from the Prostate adenocarcinoma (TCGA Firehose Legacy) in cbiportal
105 (<https://www.cbiportal.org/>), we examined quartiles of increasing age at time of diagnosis to
106 identify what genes are incrementally altered with increasing age of diagnosis³².

107

108 **Genomic alteration analysis of *ENOX1*, *CCDC122* and *LACC1*.**

109 Of 491 samples/patients that had mRNA expression z-scores relative to all samples (log mRNA
110 Seq V2 RSEM) we used the onco query language “*ENOX1*: HOMDEL, *CCDC122*: HOMDEL,
111 *LACC1*: HOMDEL” as the user defined list, the mRNA expression z-score relative to all samples,
112 in addition to putative copy number alteration from GISTIC and mutations were queried from the
113 study samples with mutation and Copy Number Alteration (CNA) data.

114 The z-score threshold was left at ± 2.0 . All other parameters were left as default.

115

116 Effect of *ENOX1*, *CCDC122* and *LACC1* in PCa

117 We examined mRNA seq data Z-score relative to all genes for patients that had deep deletions
118 for each of the three genes to compare their individual and combined effect on the survival of
119 PCa patients as overall survival.

120

121 Relationship analysis for *ENOX1*, *CCDC122* and *LACC1*.

122 Using data from String database (available at <https://string-db.org/>) the three protein names
123 were searched for under the “Multiple proteins” tab for “*Homo sapiens*” as the organism³³.

124

125 **Pathway analysis using Enrichr and Reactome**

126 To examine what genes are upregulated following the deep deletion of the three genes, we found
127 patient samples’ mRNA expression (RNA Seq V2 RSEM) (491 samples) data that had at least
128 one deep deletion of *ENOX1*, *CCDC122* and *LACC1* (altered group of 81) and those with deep
129 deletions of all three genes (unaltered).

130 As our interest was pathway analysis of genes implicated with deep deletion of all 3 genes
131 (*ENOX1*, *CCDC122* and *LACC1*), we selected for the “unaltered” gene category list with
132 statistically significant expression (95%CI) and ordered these by descending log₂ ratio of the z-
133 score absolute values then by ascending p-value. All 432 genes were used as input for pathway
134 analysis in Enrichr (<https://maayanlab.cloud/Enrichr/>) and later Reactome (<https://reactome.org/>)
135 for cross reference^{34,35}. The gene names were pasted in both analysis webpages and all
136 parameters were left as default in the analysis tab.

137 Individual gene deep deletion effect on physiological pathways was not considered for analysis
138 as patient data showed a multigene effect compounding disease status.

139

140 In Enricher, the most up-to-date manually curated pathway reference database and the highest
141 combined score for the top 4 pathways identified were chosen as the best reference database for
142 pathway analysis of the set of 432 genes.

143

144 **Statistical analysis**

145 All statistical analysis was done within cbiportal.

146

147

148 **Results**

149 **Data retrieval /overview of Prostate Adenocarcinoma study (TCGA, Firehose Legacy).**

150 To examine for genes increasingly mutated with progressing disease, we chose a cohort of PCa
151 patients with a wide range of age at time of diagnosis and Gleason primary and secondary
152 patterns. Our chosen patient cohort with mRNA seq data for 498 patient samples suited well for
153 downstream analyses for PCa genomic analysis. (Figure1).

154

155 **Figure 1| Wide scope of age of diagnosis and Gleason scores.** A shows age class boundaries of
156 patients diagnosed with PCa. B represents different primary whereas C shows the secondary Gleason
157 patterns making up different Gleason scores of PCa in patients.

158
 159 Differential gene mutation with increasing age
 160 Increasing age quartiles of PCa diagnosed patients showed differential genomic alterations.
 161 Three of the genomically altered genes; *ENOX1*, *CCDC122* and *LACC1* had increasing gene
 162 deep deletions with increasing age at time of diagnosis with 0.0883, 0.146 and 0.146 p-values
 163 respectively. (Figure 2)

164 All three genes were located on the 13q14.11 cytogenetic band having a deep deletion mutation.
 165
 166 **Figure 2| Genomically altered genes with increasing age quartiles** *ENOX1*, *CCDC122* and *LACC1*
 167 are increasingly altered with increasing age of diagnosis.

168
 169 **Genomic alteration analysis of *ENOX1*, *CCDC122* and *LACC1*.**

170 Sixteen percent (16%) of the 491 patient cohort had deep deletions of all three genes. All the
 171 three gene deep deletions had a co-occurrence tendency with p-values all less than 0.001 (95%
 172 CI) (Table1).

173
 174 **Table 1| *ENOX1*, *CCDC122* and *LACC1* are concurrently deleted in in 491 patient samples**

A	B	Neither	A Not B	B Not A	Both	Log2 Odds Ratio	p-Value	q-Value	Tendency
<i>ENOX1</i> : HOMDEL	<i>CCDC122</i> : HOMDEL	412	0	0	79	>3	<0.001	<0.001	Co-occurrence
<i>CCDC122</i> : HOMDEL	<i>LACC1</i> : HOMDEL	410	2	0	79	>3	<0.001	<0.001	Co-occurrence
<i>ENOX1</i> : HOMDEL	<i>LACC1</i> : HOMDEL	410	2	0	79	>3	<0.001	<0.001	Co-occurrence

175
 176 Analysis of any mutational data on the 3 genes irrespective of expression profile showed no
 177 patient had any mutation in the protein product of any of the (Supplementary figure 1)

178
 179 **Effect of *ENOX1*, *CCDC122* and *LACC1* deep deletion in PCa**

180 There was no significant difference in overall survival between patient who had a deep deletion
 181 and those who had an amplification of all three genes on a Kaplan-Meier plot (Supplementary
 182 figure 2)

183
 184 **Relationship analysis for *ENOX1*, *CCDC122* and *LACC1*.**

185 *CCDC122* and *LACC1* proteins were found to be co-expressed with in addition to text mining
 186 results. *ENOX1*, had no shown relationship with either gene (Figure 3).

187
 188 **Figure 3| *ENOX1* has not protein relationship with, *LACC1* and *CCDC122* which were liked with evidence**
 189 **of co-expression and text mining The three putative interactions were circled in red (*LACC1* and**
 190 ***CCDC122*) and black(*ENOX1*).**

191
 192 **Pathway analysis using Enrichr and Reactome.**

193 Reactome2022 was the database with the highest combined scores and most up-to-date in
 194 Enrichr pathway analysis. The individual gene deep deletion implicated pathways were identical
 195 between *LACC1* and *CCDC122* with *ENOX1* having a more alike effect to the combined effect of

196 all three gene deep deletions.

197 The top 5 identified pathways ranking first by descending combined score then by ascending p-
 198 value for all three genes' deep deletion were estrogen biosynthesis, KH-type splicing regulatory
 199 protein(KSRP), alpha linoleic and linoleic acid metabolism, and Rap1 signalling with
 200 114.62,110.08,82.59,67.35,56.94(2dp) combine scores respectively (Table 2).

201

202 **Table 2|** Top five upregulated genes were from estrogen biosynthesis, KSRP activity, omega 3
 203 and, 6 and, Rap1 signalling pathway.

Index	Name/Pathway Identifier	P-value	Odds Ratio	Combined score	Genes overlap
1	Estrogen Biosynthesis R-HSA-193144	0.006562	22.8030303	114.6185	<i>AKR1B15;CYP19A1</i>
2	KSRP (KHSRP) Binds and Destabilizes mRNA R-HSA-450604	4.05E-04	14.09187534	110.0775	<i>DIS3;EXOSC8;PARN;YWHAZ</i>
3	Alpha-Linolenic (Omega3) And Linoleic (Omega6) Acid Metabolism R-HSA-2046104	0.00242	13.70957944	82.58704	<i>ELOVL1;MUSK;SYCP2</i>
4	Linoleic Acid (LA) Metabolism R-HSA-2046105	0.011904	15.2004662	67.3514	<i>ELOVL1;MUSK</i>
5	Rap1 Signalling R-HSA-392517	0.004516	10.5442128	56.93941	<i>RAP1B;RAP1A;YWHAZ</i>

204

205 Results from Reactome corroborated the same pathways as identified by Enrichr displaying
 206 genes that overlapped with those from known pathways (False Discovery Rate (FDR)<0.001).
 207 The top two of these with respective overlapping genes were highlighted (Figure 4). 184 genes
 208 were not mapped to any pathway by Reactome.

209

210 **Figure 4|** Gene's overlap (coloured yellow) between query genes mapped to known pathways by
 211 Reactome. Top is the estrogen biosynthesis pathway and bottom is the KSRP binding and destabilisation
 212 of mRNA pathway.

213

214 **Discussion**

215 Our study aimed to identify some of the most prevalent genomic alterations and or differentially
 216 expressed genes throughout the progression of disease. As age at diagnosis is often positively
 217 correlated and had previously been found to be linked with disease progression and poor
 218 prognosis, we examined quartiles of ages of patients diagnosed with prostate cancer to identify
 219 those genes whose alteration frequency was increasing with age and Gleason
 220 score(Figure1)^{36,37}.

221 Whereas the development and progression of prostate cancer is not pivotal on a single or only
222 genomic mutations, we observed roles such as structural alterations and fusions attributed to
223 *TPMRSS2* gene and other chromosome 13q gene deletions among a hallmark of other factors
224 PCa employs to develop, evade and progress in an individual. *ENOX1*, one of our identified
225 genes is found on the same chromosome arm and we were able to identify its combined role with
226 *CCDC122* and *LACC1* within the same cytogenetic band of 13q14.11 in progression of PCa as
227 coexpression^{38,39}.

228

229 All the top 5 pathways implicated by upregulated genes following deep deletion of *ENOX1*,
230 *LACC1* and, *CCDC122* have been previously linked to cancer progression and give insight on
231 the beneficial effect of the three gene deletion to prostate cancer cell survival and disease
232 progression. The enriched pathways as a result of all three gene deletions were identical to those
233 enriched by *ENOX1* single gene deletion alone whereas single gene deletion of *LACC1* and
234 *CCDC122* had the same not identical effect to the pathways enriched by all three gene deletions
235 (Supplementary figure 3). This suggests that the overall observed enriched pathways were more
236 as a result of single gene deletion of *ENOX1* that either or both of *LACC1* and *CCDC122*.

237 Estrogen has been shown to play a role in the development and progression of prostate cancer
238 through its receptor activation on PCa cells that promotes cell proliferation and survival⁴⁰⁻⁴².

239 Estrogen can stimulate the production of growth factors and cytokines that promote angiogenesis
240 and tumour growth^{40,41,43}. Estrogen can inhibit the androgen receptor (AR) signalling pathway,
241 and this is important for prostate cancer growth and survival^{40,43}.

242

243 KSRP (KH-type splicing regulatory protein) is an RNA-binding protein that has been shown to
244 promote tumour growth and metastasis in non-small cell lung, breast, ovarian and, prostate
245 cancer⁴⁴. A study on castration-resistant prostate cancer showed that KSRP regulates type III
246 interferon expression post-transcriptionally, which is an important axis in the progression of
247 prostate cancer especially in advanced stage⁴⁵. KSRP is also known to regulate gene expression
248 on various levels, including gene transcription, mRNA decay, and microRNA precursor
249 maturation⁴⁴. In colorectal cancer, enhanced expression of KSRP was found in tumour tissue and
250 was associated with worse overall survival. KSRP seemed to drive epithelial cell proliferation in
251 primary and metastatic cells through control of cell cycle progression and promoted angiogenesis
252 by enhancing vascular endothelial growth factor⁴⁶.

253

254 Omega-3 and omega-6 fatty acids play a crucial role in the development and progression of
255 prostate cancer. High amounts of omega-6 fatty acids have been linked with an increased risk of
256 prostate cancer, whereas omega-3 fatty acids have been shown to inhibit prostate cancer
257 growth⁴⁷. A study on athymic mouse xenograft model simulating radical prostatectomy showed
258 that prostate tumours can be modulated by the manipulation of omega-6:omega-3 ratios through
259 diet, and the omega-3 fatty acid stearidonic acid (SDA) (precursor of eicosapentaenoic acid
260 (EPA)) can inhibit prostate tumour growth and recurrence⁴⁸. However, a study found that high
261 intake of omega-3 fats in the blood is linked to an increased risk of prostate cancer⁴⁹. Another
262 study showed that there were no significant associations between specific omega-3 or omega-6
263 PUFA intakes and overall prostate cancer risk⁵⁰. Our current findings show a beneficial role of
264 these two essential acids in PCa.

265
266 Ras-proximate-1 (Rap1) signalling has been shown to play a role in prostate cancer metastasis
267 and invasion⁵¹⁻⁵³. Specifically, Rap1 promotes tumour progression by disrupting E-cadherin-
268 mediated cell adhesion, leading to a reduction in E-cadherin⁵⁴. Activation of Rap1 has also been
269 shown to increase prostate cancer cell migration and invasion through the $\alpha 4$, $\beta 3$, and $\alpha v\beta 3$
270 integrins⁵³. Additionally, a study found that miR-203 down-regulates Rap1A and subsequently
271 suppresses cell proliferation, adhesion, and invasion in prostate cancer⁵³. These studies
272 summatively suggest Rap1 contributes to PCa metastasis and, invasion in patients through
273 several pathways

274
275 Whereas our initial supposition was that *ENOX1*, *LACC1* and *CCDC122* were increasingly
276 expressed to benefit PCa, our findings show that their deletion instead enriches genes that
277 achieve the same outcome of PCa cell growth and survival.

278 The novelty in our findings is the link between the three identified genes whose combined
279 deletions enriches genes in in PCa cell benefiting pathways for disease cell growth and survival.
280 The three gene protein products, however, have positive physiological body functions so it is
281 putative that on deletion, redundant functionality from similar proteins whose deletion would be
282 detrimental to PCa cells is employed as a substitute.

283
284 For a wet lab proof of concept, future work might involve use of PCa cell lines (RWPE-1, LNCaP,
285 PC3, DU145) demonstrating different stage progression or stem cells of the disease and
286 screening for the three genes using fluorescent *in-situ* hybridisation technique under the
287 expectation of decreasing fluorescence with advancing disease.

288 As a therapeutic target for PCa and personalised therapy, judicious targeting of rate limiting
289 steps/enzymes in the identified pathways could be explored as a treatment option should the
290 side effect not outweigh the clinical benefit of the intervention.

291
292 **Acknowledgments.**




293 Special appreciation to Dr. Amanda Coutts (P.H.d) and the School of Science and Technology
294 for the guidance and resources used in executing this work.


295
296 **References**


- 297 1. Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality
298 Worldwide for 36 Cancers in 185 Countries. *CA. Cancer J. Clin.* **71**, 209–249 (2021).
- 299 2. Chhikara, B. S. & Parang, K. Global Cancer Statistics 2022: the trends projection analysis. *Chem.*
300 *Biol. Lett.* **10**, Vol. 10 No. 1 (2023) (2023).
- 301 3. Prostate cancer incidence statistics | Cancer Research UK.
302 [https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading=Three)
303 [type/prostate-cancer/incidence#heading=Three](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading=Three) (2023).
- 304 4. Hatzoglou, V. *et al.* Brain Metastases from Prostate Cancer: An 11-Year Analysis in the MRI Era
305 with Emphasis on Imaging Characteristics, Incidence, and Prognosis. *J. Neuroimaging* **24**, 166–
306 166 (2014).
- 307 5. Caster, J. M., Falchook, A. D., Hendrix, L. H. & Chen, R. C. Risk of pathologic upgrading or locally
308 advanced disease in early prostate cancer patients based on biopsy gleason score and PSA: A
309 population-based study of modern patients. *Int. J. Radiat. Oncol. Biol. Phys.* (2015)
310 doi:10.1016/j.ijrobp.2015.01.051.
- 311 6. Carroll, P. H. & Mohler, J. L. NCCN guidelines updates: Prostate cancer and prostate cancer

- 312 early detection. *JNCCN J. Natl. Compr. Cancer Netw.* **16**, 620–623 (2018).
- 313 7. Held-Warmkessel, J. Treatment of advanced prostate cancer. *Semin. Oncol. Nurs.* **17**, 118–128
314 (2001).
- 315 8. Nanus, D. M. *et al.* Clinical use of monoclonal antibody HuJ591 therapy: Targeting prostate
316 specific membrane antigen. in *Journal of Urology* (2003). doi:10.1097/01.ju.0000095151.97404.7c.
- 317 9. Luo, C., Chen, J. & Chen, L. Exploration of gene expression profiles and immune
318 microenvironment between high and low tumor mutation burden groups in prostate cancer. *Int.*
319 *Immunopharmacol.* **86**, (2020).
- 320 10. Wang, L., Pan, S., Zhu, B., Yu, Z. & Wang, W. Comprehensive analysis of tumour mutational
321 burden and its clinical significance in prostate cancer. *BMC Urol.* **21**, 1–10 (2021).
- 322 11. Lawlor, R. T. *et al.* Tumor mutational burden as a potential biomarker for immunotherapy in
323 pancreatic cancer: Systematic review and still-open questions. *Cancers (Basel).* **13**, (2021).
- 324 12. Kluth, M. *et al.* 13Q Deletion Is Linked To an Adverse Phenotype and Poor Prognosis in Prostate
325 Cancer. *Genes Chromosom. Cancer* **57**, 504–512 (2018).
- 326 13. Chalmers, Z. R. *et al.* Analysis of 100,000 human cancer genomes reveals the landscape of
327 tumor mutational burden. *Genome Med.* **9**, (2017).
- 328 14. Venkateswaran, A. *et al.* The NADH Oxidase ENOX1, a Critical Mediator of Endothelial Cell
329 Radiosensitization, Is Crucial for Vascular Development. *Cancer Res.* **74**, 38–43 (2014).
- 330 15. Jiang, Z., Gorenstein, N. M., Morr , D. M. & James Morr , D. Molecular cloning and
331 characterization of a candidate human growth-related and time-keeping constitutive cell surface
332 hydroquinone (NADH) oxidase. *Biochemistry* **47**, 14028–14038 (2008).
- 333 16. Wu, Y. *et al.* Identification of the Functions and Prognostic Values of RNA Binding Proteins in
334 Bladder Cancer. *Front. Genet.* **12**, 1–19 (2021).
- 335 17. Science for Life laboratory, K. I. NM_001347969.2(ENOX1):c.759_765del (p.Ser254fs) AND
336 Malignant tumor of prostate - ClinVar - NCBI. <https://www.ncbi.nlm.nih.gov/clinvar/RCV000149057/>
337 (2023).
- 338 18. Kluth, M. *et al.* Prevalence of chromosomal rearrangements involving non-ETS genes in prostate
339 cancer. *Int. J. Oncol.* **46**, 1637–1642 (2015).
- 340 19. Uhlen, M. *et al.* A pathology atlas of the human cancer transcriptome. *Science (80-.).* **357**,
341 (2017).
- 342 20. Expression of ENOX1 in cancer - Summary - The Human Protein Atlas.
343 <https://www.proteinatlas.org/ENSG00000120658-ENOX1/pathology> (2023).
- 344 21. Cheng, H. L., Lee, Y. H., Yuan, T. M., Chen, S. W. & Chueh, P. J. Update on a tumor-associated
345 NADH oxidase in gastric cancer cell growth. *World J. Gastroenterol.* **22**, 2900–2905 (2016).
- 346 22. Safran, M. *et al.* GeneCards™ 2002: towards a complete, object-oriented, human gene
347 compendium. *Bioinformatics* **18**, 1542–1543 (2002).
- 348 23. Bartha,  ., Gy, B. & Orffy,  . Molecular Sciences TNMplot.com: A Web Tool for the Comparison of
349 Gene Expression in Normal, Tumor and Metastatic Tissues. (2021) doi:10.3390/ijms22052622.
- 350 24. Xiong, J. H. *et al.* Association between genetic variants in NOD2, C13orf31, and CCDC122 genes
351 and leprosy among the Chinese Yi population. *Int. J. Dermatol.* **55**, 65–69 (2016).
- 352 25. Leturiondo, A. L. *et al.* Association of NOD2 and IFNG single nucleotide polymorphisms with
353 leprosy in the Amazon ethnic admixed population. *PLoS Negl. Trop. Dis.* **14**, 1–13 (2020).
- 354 26. Fagerberg, L. *et al.* Analysis of the Human Tissue-specific Expression by Genome-wide
355 Integration of Transcriptomics and Antibody-based Proteomics* □ S. (2013)
356 doi:10.1074/mcp.M113.035600.
- 357 27. LACC1 Gene - GeneCards | LACC1 Protein | LACC1 Antibody. [https://www.genecards.org/cgi-](https://www.genecards.org/cgi-bin/carddisp.pl?gene=LACC1)
358 [bin/carddisp.pl?gene=LACC1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=LACC1) (2023).
- 359 28. Lahiri, A., Hedl, M., Yan, J. & Abraham, C. Human LACC1 increases innate receptor-induced
360 responses and a LACC1 disease-risk variant modulates these outcomes. *Nat. Commun.* **8**, (2017).
- 361 29. Huang, C., Hedl, M., Ranjan, K. & Abraham, C. LACC1 Required for NOD2-Induced, ER Stress-
362 Mediated Innate Immune Outcomes in Human Macrophages and LACC1 Risk Variants Modulate
363 These Outcomes. *Cell Rep.* **29**, 4525 (2019).
- 364 30. Li, S. *et al.* Transcriptome analysis of differentially expressed genes and pathways associated
365 with mitoxantrone treatment prostate cancer. *J. Cell. Mol. Med.* **23**, 1987–2000 (2019).

- 366 31. Luca, B.-A. Identification of biomarkers for the management of human prostate cancer. (2017).
367 32. Gao, J. *et al.* Integrative analysis of complex cancer genomics and clinical profiles using the
368 cBioPortal. *Sci. Signal.* **6**, (2013).
369 33. Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with increased coverage,
370 supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* **47**,
371 D607–D613 (2019).
372 34. Kuleshov, M. V *et al.* Enrichr: a comprehensive gene set enrichment analysis web server 2016
373 update. *Nucleic Acids Res.* **44**, W90–W97 (2016).
374 35. Gillespie, M. *et al.* The reactome pathway knowledgebase 2022. *Nucleic Acids Res.* **50**, (2021).
375 36. Pettersson, A. *et al.* Age at diagnosis and prostate cancer treatment and prognosis: a population-
376 based cohort study. *Ann. Oncol.* **29**, 377–385 (2018).
377 37. Cooney, M. M., Okuku, F. & Orem, J. Prostate Cancer Burden at the Uganda Cancer Institute. **2**,
378 181–185 (2019).
379 38. Perner, S. *et al.* TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with
380 invasion. *Am. J. Surg. Pathol.* **31**, 882–888 (2007).
381 39. Braun, M. ERG rearrangement is specific to prostate cancer and does not occur in any other
382 common tumor. (2012).
383 40. Bosland, M. C. SELECTIVE ESTROGEN RECEPTOR MODULATORS The Role of Estrogens in
384 Prostate Carcinogenesis: A Rationale for Chemoprevention. *Rev. Urol.* **7**, (2005).
385 41. Ramírez-de-Arellano, A. *et al.* Distribution and Effects of Estrogen Receptors in Prostate Cancer:
386 Associated Molecular Mechanisms. *Front. Endocrinol. (Lausanne)*. **12**, 811578 (2022).
387 42. Malaguartera, R. *et al.* estrogens and Their Receptors in Prostate Cancer: Therapeutic
388 implications. **8**, (2018).
389 43. Nelles, J. L., Hu, W.-Y. & Prins, G. S. Estrogen action and prostate cancer. (2011)
390 doi:10.1586/eem.11.20.
391 44. Gherzi, R., Chen, C. Y., Trabucchi, M., Ramos, A. & Briata, P. The role of KSRP in mRNA decay
392 and microRNA precursor maturation. *Wiley Interdiscip. Rev. RNA* **1**, 230–239 (2010).
393 45. Schmidtke, L. *et al.* The KH-type splicing regulatory protein (KSRP) regulates type III interferon
394 expression post-transcriptionally. *Biochem. J.* **476**, 333–352 (2019).
395 46. Palzer, K. A. *et al.* The Role of KH-Type Splicing Regulatory Protein (KSRP) for Immune
396 Functions and Tumorigenesis. *Cells* **11**, (2022).
397 47. Apte, S. A., Cavazos, D. A., Whelan, K. A. & Degraffenried, L. A. A low dietary ratio of omega-6
398 to omega-3 Fatty acids may delay progression of prostate cancer. *Nutr. Cancer* **65**, 556–562
399 (2013).
400 48. Kelavkar, U. P. *et al.* Prostate tumor growth and recurrence can be modulated by the omega-
401 6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy.
402 *Neoplasia* **8**, 112–124 (2006).
403 49. Brasky, T. M. *et al.* Plasma Phospholipid Fatty Acids and Prostate cancer risk in the Select trial.
404 **105**, (2013).
405 50. Huerta-Yépez, S., Tirado-Rodríguez, A. B. & Hankinson, O. Role of diets rich in omega-3 and
406 omega-6 in the development of cancer. *Bol. Med. Hosp. Infant. Mex.* **73**, 446–456 (2016).
407 51. Zhang, Y. L., Wang, R. C., Cheng, K., Ring, B. Z. & Su, L. Roles of Rap1 signaling in tumor cell
408 migration and invasion. *Cancer Biol. Med.* **14**, 90–99 (2017).
409 52. Bailey, C. L., Kelly, P. & Casey, P. J. Activation of Rap1 Promotes Prostate Cancer Metastasis.
410 *Cancer Res.* **69**, 4962 (2009).
411 53. Jaśkiewicz, A., Pajka, B. & Orzechowski, A. The many faces of rap1 GTPase. *Int. J. Mol. Sci.* **19**,
412 1–20 (2018).
413 54. Looi, C. K., Hii, L. W., Ngai, S. C., Leong, C. O. & Mai, C. W. The Role of Ras-Associated Protein
414 1 (Rap1) in Cancer: Bad Actor or Good Player? *Biomedicines* **8**, (2020).








bioRxiv preprint doi: <https://doi.org/10.1101/2023.10.12.23296974>; this version posted October 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Estrogen Biosynthesis

CYP19A1



medRxiv preprint doi: <https://doi.org/10.1101/2023.10.12.23296974>; this version posted October 13, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

AKR1B1

